V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Non-neutralizing IgG to the V1V2 loop of HIV-1 gp120 correlates with a decreased risk of HIV-1 infection but the mechanism of protection remains unknown. This V1V2 IgG correlate was identified in RV144 Thai trial vaccine recipients, who were primed with a canarypox vector expressing membrane-bound g...

Full description

Bibliographic Details
Main Authors:	Lautaro G Perez, David R Martinez, Allan C deCamp, Abraham Pinter, Phillip W Berman, Donald Francis, Faruk Sinangil, Carter Lee, Kelli Greene, Hongmei Gao, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Robert J O'Connell, Merlin L Robb, Nelson L Michael, Jerome H Kim, Peter Gilbert, David C Montefiori
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5498072?pdf=render

Similar Items

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.
by: Punnee Pitisuttithum, et al.
Published: (2015-01-01)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
by: Choi, Ickwon, et al.
Published: (2015)

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees.
by: Ickwon Choi, et al.
Published: (2015-04-01)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
by: Stephanie Fischinger, et al.
Published: (2020-11-01)

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
by: Raphael Gottardo, et al.
Published: (2013-01-01)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
by: Nathan I. Nicely, et al.
Published: (2015-07-01)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
by: McLellan JS, et al.
Published: (2012-09-01)

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.
by: Paul T Edlefsen, et al.
Published: (2015-02-01)

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
by: Kalpana Dommaraju, et al.
Published: (2014-01-01)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
by: Siriwat Akapirat, et al.
Published: (2018-01-01)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
by: Slim Fourati, et al.
Published: (2019-02-01)

RV144 HIV-1 vaccination impacts post-infection antibody responses.
by: Thembi Mdluli, et al.
Published: (2020-12-01)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses.
by: Thembi Mdluli, et al.
Published: (2021-03-01)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
by: David Easterhoff, et al.
Published: (2017-02-01)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
by: Kristina K Peachman, et al.
Published: (2015-01-01)

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
by: Susan Zolla-Pazner, et al.
Published: (2014-01-01)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
by: Francis D, et al.
Published: (2009-10-01)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
by: Jerome H. Kim, et al.
Published: (2013-08-01)

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
by: Punnee Pitisuttithum, et al.
Published: (2011-01-01)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
by: Peter B Gilbert, et al.
Published: (2017-01-01)

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.
by: Silvia Ratto-Kim, et al.
Published: (2015-01-01)

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
by: Susan Zolla-Pazner, et al.
Published: (2014-11-01)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
by: Hertz T, et al.
Published: (2012-09-01)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
by: Liao L, et al.
Published: (2012-09-01)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
by: Karasavvas N, et al.
Published: (2012-09-01)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
by: Sarah Auclair, et al.
Published: (2018-02-01)

A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
by: Melissa M. Lemke, et al.
Published: (2021-09-01)

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.
by: Susan Zolla-Pazner, et al.
Published: (2013-01-01)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
by: Yu B, et al.
Published: (2012-09-01)

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
by: Bonsignori M, et al.
Published: (2012-09-01)

Reply to R.V. Patel et al
by: Masanori Mori, et al.
Published: (2023-09-01)

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
by: Shida Shangguan, et al.
Published: (2021-09-01)

Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine
by: Viravarn Luvira, et al.
Published: (2024-12-01)

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
by: Supitcha Kamolratanakul, et al.
Published: (2021-11-01)

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand
by: Punnee Pitisuttithum, et al.
Published: (2019-10-01)

AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.
by: Stephen J Kent, et al.
Published: (2010-09-01)

HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen
by: Qian Wang, et al.
Published: (2017-01-01)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
by: Chiu J, et al.
Published: (2009-10-01)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
by: Pollara J, et al.
Published: (2012-09-01)

Amerikiečio žvilgsnis į Lietuvos archeologiją. Pastabos R.V. Sidrio straipsnio paraštėse
by: Mykolas Michelbertas
Published: (2001-12-01)